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Background: DNA topoisomerases are key enzymes that modulate the topological state of DNA through the breaking
and rejoining of DNA strands. Human topoisomerase I belongs to the family of poly(ADP-ribose)-binding proteins and
is the target of camptothecin derived anticancer drugs. Poly(ADP-ribosyl)ation occurs at specific sites of the enzyme
inhibiting the cleavage and enhancing the religation steps during the catalytic cycle. Thus, ADP-ribose polymers
antagonize the activity of topoisomerase I poisons, whereas PARP inhibitors increase their antitumor effects.
Methods: Using site-directed mutagenesis we have analyzed the interaction of human topoisomerase I and poly
(ADP-ribose) through enzymatic activity and binding procedures.
Results: Mutations of the human topoisomerase I hydrophobic or charged residues, located on the putative
polymer binding sites, are not sufficient to abolish or reduce the binding of the poly(ADP-ribose) to the protein.
These results suggest either the presence of additional binding sites or that the mutations are not enough
perturbative to destroy the poly(ADP-ribose) interaction, although in one mutant they fully abolish the enzyme
activity.
Conclusions: It can be concluded that mutations at the hydrophobic or charged residues of the putative
polymer binding sites do not interfere with the ability of poly(ADP-ribose) to antagonize the antitumor activity of
topoisomerase I poisons.
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Poly(ADP-ribosyl)ation (PARylation) is a post-translational
modification of proteins catalyzed by the poly(ADP-ribose)
polymerase (PARP) family of enzymes, of which PARP-1 is
the best characterized member [1]. The ADP-ribose mono-
mers are cleaved by PARP enzymes from NAD+ donor and
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unless otherwise stated.(PARs) that are covalently linked to glutamic, aspartic
and lysine amino acids of target proteins, such as his-
tones, transcription factors and PARP-1 itself, which is
the main acceptor of PARs. Through PAR-mediated
auto-modification and heteromodification of proteins,
PARP-1 regulates a number of cellular processes in-
cluding DNA damage detection/repair, chromatin re-
modeling, transcription control, differentiation and cell
death [2]. Covalently attached PARs have a rapid turn-
over, since they are quickly hydrolyzed to free PARs or
mono(ADP-ribose) by PAR glycohydrolase (PARG) [3].
PARylated PARP-1 or free PARs, that are highly flex-
ible polymers [4], can also non-covalently interact with a
variety of proteins containing a PAR binding motif
(PBM), which includes basic and hydrophobic residues
downstream of a positively charged cluster rich in lysinel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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teins involved in DNA damage response, chromatin
structure, replication and transcription and can be
present in different domains of the same target protein.
Other motifs or domains capable of interacting with
PARs comprise: i) the glycine and arginine rich domain
(GAR) lacking hydrophobic amino acids, identified in pro-
teins involved in RNA metabolism and in some chromatin
associated proteins; ii) the RNA recognition motif (RRM)
and the serine/arginine repeats (SR) domain, both present
in proteins implicated in nucleic acid metabolism; iii) the
PAR-binding zinc finger (PBZ), found only in three human
proteins related to PAR metabolism; iv) the WWE do-
main, in which tryptophan (W) and glutamate (E) are the
most conserved amino acids and that has been reported
in proteins associated with ubiquitylation and PARylation;
v) the macro domain, present in some PARPs, histone
variants and capable of binding to PARs or ADP-ribose
and O-acetyl-ADP-ribose [9]. Since PARs are negatively
charged molecules, they profoundly alter the biochemical
properties of the covalently-modified acceptors or pro-
teins non-covalently interacting with PARs, modulating
their structure, function and localization.
Human topoisomerase I (hTop1) has been identified as
a protein that non-covalently interacts with PARs [10].
HTop1 is composed of 765 amino acids and four different
domains: the NH2-terminal (residues 1–214), the core
(215–635), the linker (636–712), and the COOH-terminal
domain (713–765) [11]. The enzyme relaxes a supercoiled
DNA substrate cleaving one strand, facilitating the rota-
tion of one strand over the other and religating the
cleaved strand after relaxation is occurred. HTop1 is of
significant medical interest being the target of antitumor
agents derived from camptothecin (CPT). In particular,
irinotecan is approved with 5-fluorouracil and leucovorin
for the first line treatment of metastatic colorectal cancer
and as monotherapy for the treatment of disease recur-
rence or progression following fluorouracil-based therapy
[12]. Topotecan, instead, is currently used for the treat-
ment of metastatic ovarian cancer and small cell lung can-
cer after failure of first-line chemotherapy.
CPT reversibly binds to the covalent intermediate
DNA-enzyme, stabilizing the cleavable complex and redu-
cing the rate of religation. The stalled hTop1 complex col-
lides with the progressing replication fork producing
lethal double-stranded DNA breaks and cell death [13]. In
vitro both the cleavage and religation reactions can be
modulated by PARs [10]. In detail, DNA cleavage is inhib-
ited, whilst the religation activity is enhanced, even when
the enzyme is stalled with the CPT drug, in presence of
PARs. Therefore, PARs counteract the effects of hTop1
poisons. Accordingly, PARP inhibitors remove the antag-
onistic effect exerted by PARs on the mechanism of action
of hTop1 poisons, increasing the formation of persistentDNA breaks. Indeed, the combination of PARP inhibitors
with the CPT derivatives irinotecan or topotecan resulted
in synergistic antitumor effects in preclinical tumor
models and is under evaluation in clinical trials for the
treatment of a number of refractory malignancies [14-19]
(www.clinicaltrials.gov).
Three putative PBM, supposed to be present in hTop1,
have been identified, two of them are positioned in the
core DNA-binding domain (amino acids 261–280 and
532–551, respectively), whereas the third one is in the
linker domain (amino acids 669–688) that connects the
core with the C-terminal domain where the catalytic
tyrosine is located (Figure 1) [10]. However it has never
been demonstrated that they are indispensable for the
PAR binding or if they are selectively involved in the
modulation of the cleavage and religation activity. In this
study, in the effort to identify the functional role of PAR
binding sites, we have produced two hTop1 mutants
where eight basic (8bmut) and eight hydrophobic
(8hmut) residues present in the three PMB have been
eliminated and replaced with neutral alanines, in order
to test the binding of PARs and the resulting modulation
of hTop1 activity in the absence or in the presence of
CPT. The basic residues were selected because they can
be important in mediating an electrostatic interaction
with the negatively charged PARs, whilst hydrophobic
residues can have a crucial role in defining the conform-
ation of the motif. The results show that the two mu-
tants still bind PARs, indicating either the presence of
additional PAR binding sites or that the drastic muta-
tions are not enough to destroy the PAR interaction.
Methods
Yeast strains, plasmids and purification
Anti-FLAG M2 monoclonal affinity gel, FLAG peptide,
anti-FLAG M2 monoclonal antibody were purchased
from Sigma-Aldrich and the antibody against the C-
terminus of hTop1 from Abcam.
Saccharomyces cerevisiae Top1 null strain EKY3 (ura3-
52, his3Δ200, leu2Δ1, trp1Δ63, top1::TRP1, MATα) was
used to express the hTop1 gene. YCpGAL1-e-hTop1 sin-
gle copy plasmid was previously described [20].
The 8bmut and the 8hmut mutants were generated using
a site-directed-mutagenesis kit (Agilent Technologies) of
the YCpGAL1-hTop1 in which the hTop1 is expressed
under the galactose inducible promoter in a single-copy
plasmid. The epitope-tagged construct YCpGAL1-e-hTop1
contains the N-terminal sequence FLAG: DYKDDDDY
(indicated with ‘e’), recognized by the M2 monoclonal
antibody. The epitope-tag was subcloned into YCpGAL1-
hTop18bmut or YCpGAL1-hTop18hmut to produce the
YCpGAL1-e-hTop18bmut and YCpGAL1-e-hTop18hmut.
The plasmids were transformed into XL10-Gold E. coli
cells (Agilent Technologies) and, then, extracted using
K IFRK F
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hTop1 261-280: AKMLDHEYTT E N FK
hTop1 532-551: KDSIRYYNKVP E KNL
hTop1 669-688: KADAK M D KT K VESKK
PBM: x x
Figure 1 Three-dimensional representation of the hTop1 protein-DNA binary complex. The lateral chains of the residues forming the three
putative PAR binding sites have been mapped on the hTop1 structure. The positively charged residues are shown in red and the hydrophobic
ones in green.
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sequencing the hTop1 gene of the extracted plasmids.
After the transformation in EKY3 yeast strain, the purifi-
cation of hTop1 proteins was carried out essentially as
previously described [21].
Relaxation assay
The activity of equal amounts of wild-type or 8bmut pro-
teins was assayed in 30 μl of reaction volume containing
0.5 μg of negatively supercoiled pBlue-Script KSII(+)
DNA, which is present in both dimeric and monomeric
forms, and reaction buffer (20 mM Tris–HCl pH 7.5,
0.1 mM Na2EDTA, 10 mM MgCl2, 5 μg/ml acetylated bo-
vine serum albumin and 150 mM KCl). The effect of PARs
on hTop1 enzymatic activity was measured by adding in-
creasing pmol of PARs to the reactions that were stopped
with 0.5% SDS after 10 minutes at 37°C. In selected sam-
ples no proteins have been added as negative control or
no PARs have been added to show the full capability of re-
laxation of the proteins. The samples were resolved in a
1% (w/v) agarose gel in 48 mM Tris, 45.5 mM boric acid,
1 mM EDTA at 10 V/cm. The gels were stained with eth-
idium bromide (0.5 μg/ml), destained with water and
photographed using an UV transilluminator.
Synthesis in vitro and analysis by gel electrophoresis of
[32P]-PARs
Polymers of [32P]ADP-ribose, with high specific activity
(0.5 μCi/nmol), were synthesized in a 100 μl reactionmixture containing 100 mM Tris–HCl pH 8, 10 mM
MgCl2, 2 mM dithiothreitol, [
32P]-NAD+ (1000 Ci/mmol;
5 μCi/μl; GE Healthcare), 1 μg of purified PARP-1 (Trevi-
gen), 2.5 μg of DNase I-activated DNA (Alexis Biochemi-
cals) and 200 μM NAD+ (Sigma-Aldrich). After 45 min
incubation at 30°C the reaction was stopped by the
addition of ice-cold trichloroacetic acid and PARs were
detached from the proteins as described [22]. The concen-
tration of radiolabeled PARs was expressed as nmol
monomeric [32P]ADP-ribose/μl and calculated as previ-
ously described (dpm μl/NAD-specific radioactivity) [22].
For the synthesis of cold PARs the radiolabeled NAD+ was
omitted from the reaction mixture.
An aliquot of radiolabeled PARs (corresponding to
25,000 dpm) was loaded onto a 20% polyacrylamide gel
and electrophoresed until bromophenol blue (co-migrat-
ing with the 8-mer of ADP-ribose) reached half the
length of the gel [22,23]. Gels were dried under vacuum
and exposed to X-ray films (Kodak X-Omat).
Dot blot analysis of wild-type and hTop1 mutants
Purified wild-type and hTop1 recombinant mutants were
quantified by dot blot analysis using an antibody against
the C-terminal region of hTop1 or the anti-FLAG anti-
body conjugated with alkaline phosphatase (clone M2,
Sigma-Aldrich). In the case of immunoblot with the anti-
hTop1 antibody, the membrane was, then, incubated with
goat anti-mouse IgG horseradish peroxidase (HRP)-conju-
gated secondary antibody and immunoreactive bands were
Tesauro et al. Journal of Experimental & Clinical Cancer Research 2014, 33:71 Page 4 of 8
http://www.jeccr.com/content/33/1/71detected by enhanced chemoluminescence (ECL) tech-
nique using the ECL Plus Western Blotting Substrate
(Pierce). For the staining of immunoreactive bands of the
membranes incubated with the anti-FLAG antibody, the
NBT/BCIP substrates and solutions were used (Sigma-Al-
drich). Spots were quantified by Image J densitometry
software (National Institutes of Health, Bethesda, MD,
http://rsbweb.nih.gov/ij/).PAR binding assay
Graded amounts of purified wild-type and hTop1 mutants
were spotted on nitrocellulose membrane (0.45 μm; GE
healthcare). Histone H1 was used as positive control in
the PAR binding assay, whereas DNase I and proteinase K
were used as negative controls. Non-covalent binding of
PARs to hTop1 immobilized on nitrocellulose membrane
was assayed incubating the filter with radiolabeled PARs
(0.5 nmol) diluted in 10 ml of TBS-T (10 mM Tris–HCl
pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 h at room
temperature, as described [10]. The membrane was
washed with TBS-T buffer, until no radioactivity was de-

























Figure 2 Non-covalent PAR binding of wild-type hTop1, 8bmut and 8
nitrocellulose membrane and quantified by immunoblot analysis using ant
graded amounts of proteins were tested for non-covalent PAR binding usin
PK) and positive (50 and 25 ng histone H1) (H1) controls have been also sp
the right and the length of PAR molecules in terms of ADP-ribose residues is
and the wild-type protein after normalization with anti-hTop1 (C-terminus) or
independent experiments.Cleavage and religation assay
Oligonucleotide CL14 (5′-GAAAAAAGACTTAG-3′) that
contains a hTop1 high affinity cleavage site was 5′-end la-
beled with [γ32P]-ATP. The CP25 complementary strand
(5′-TAAAAATTTTTCTAAGTCTTTTTTC-3′) was 5′-
end phosphorylated with unlabeled ATP. The two strands
were annealed with a 2-fold molar excess of CP25 over
CL14. The suicide cleavage reactions were carried out, as a
function of the indicated PAR concentrations, by incubat-
ing 20 nM of the duplex DNA with an excess of hTop1 or
the 8bmut in 10 mM Tris pH 7.5, 5 mM MgCl2, 5 mM
CaCl2 and 150 mM KCl at 25°C in a final volume of 50 μl
[24]. At various time points 5 μl aliquots were removed
and the reaction stopped with 0.5% (w/v) SDS. After etha-
nol precipitation samples were resuspended in 5 μl of
1 mg/ml trypsin and incubated at 37°C for 60 minutes.
However, a short trypsin resistant peptide is always left
explaining why the cleavable complex (Cl) migrates
slower than the uncleaved [25]. Samples have been ana-
lyzed by denaturing 7 M urea/20% polyacrylamide gel
electrophoresis in TBE (48 mM Tris, 45.5 mM Boric
Acid, 1 mM EDTA). The percentage of cleaved substrate




Ab PAR binding PAR
tumh8
hmut. A. The wild-type hTop1, 8bmut and 8hmut were spotted on
i-hTop1 C-terminal antibody or N-terminal-FLAG antibodies. The same
g radiolabeled PARs. Negative (1 μg DNase I and 1 μg proteinase K,
otted on the membrane. The typical ladder of [32P]-PARs is shown on
indicated. B. Bars represent the ratio of the PAR binding of the mutants
N-terminal-FLAG antibodies. The values are the means ± SD of three
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in each lane and finally plotted as a function of PAR
concentrations.
For the religation assay, 20 nM of CL14/CP25 (radiola-
beled as previously described in the cleavage kinetic ex-
periment) was incubated with an excess of hTop1 or
8bmut for 60 minutes at 25°C followed by 30 minutes at
37°C in 20 mM Tris–HCl pH 7.5, 0.1 mM Na2EDTA,
10 mM MgCl2, 50 μg/ml acetylated BSA, and 150 mM
KCl. After the formation of the cleavable complex a 5 μl
aliquot was removed and used as time 0 point, then
DMSO, 100 μM CPT, PARs or CPT plus PARs were
added and religation reaction was started by adding a
200-fold molar excess of R11 oligonucleotide (5′-
AGAAAAATTTT-3′) over the CL14/CP25 [22]. Five μl
aliquots were removed at various time points, and the
reaction stopped with 0.5% SDS. After ethanol precipita-
tion, samples were resuspended in 5 μl of 1 mg/ml tryp-
sin and incubated at 37°C for 60 minutes. Samples were
analyzed by denaturing 7 M urea/20% polyacrylamide
gel electrophoresis in 48 mM Tris, 45.5 mM boric acid,
1 mM EDTA. The percentage of remaining cleavage
complex was quantified by ImageQuant software, nor-
malized to the total radioactivity for each lane and to the























Figure 3 Influence of PARs on cleavage reaction. Suicide cleavage reac
described on the top of the figure. Different concentrations of PARs were i
represents the DNA fragment cleaved by the enzyme at the preferred site.
has been plotted against different PAR concentrations for the wild-type (da
SD from 3 independent experiments.Results and discussion
The three putative PBM, which are present in the core
and linker domains of hTop1 (Figure 1), contain eight
basic amino acids (in red), likely important in mediating
an electrostatic interaction with the negatively charged
PARs, and eight hydrophobic amino acids (in green) that
might have a crucial role in defining the conformation of
the motif. Two mutants, one replacing the eight basic
(8bmut) and the other one the eight hydrophobic (8hmut)
amino acids with neutral alanines have been produced by
site directed mutagenesis. Both mutants and the wild-type
protein have been introduced in the single copy yeast plas-
mid (YCp) expressing the hTop1 under the GAL1 pro-
moter. The PAR binding has been tested using a
nitrocellulose blot assay. Serial dilutions of the two mu-
tants and the wild-type proteins have been spotted on the
nitrocellulose filter (Figure 2A), and the non-covalent
binding of radiolabeled PARs, added to the filter, has been
quantified after washing. The detection of the radioactive
signal in the three samples indicates that the mutants re-
tain the ability to bind PARs, as confirmed by the negative
(DNase I and proteinase K) and positive (histone H1) con-
trols. The quantitative analysis of the results of PAR bind-
ing assays from three independent experiments, after
normalization with the amount of hTop1 spotted on thePAR (pmol)
50  0   10  15   20  25  30  35  40   50  





tion as a function of PAR concentration, carried out with the substrate
ncubated with the wild-type or 8bmut proteins at 37°C for 30 min. Cl
Lane 1, no protein added. The percentage of cleaved suicide substrate
rk grey bar) and the 8bmut (light gray bar). Data shown are means ±
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tants is similar to that of the wild-type protein (Figure 2B).
Analysis of the specific activity of the purified hTop1,
of the 8bmut and of the 8hmut determined using a plas-
mid DNA relaxation assay indicates that the 8bmut has
an activity comparable to that of the wild-type protein,
whilst the 8hmut protein is completely inactive (data not
shown). The loss of activity of the 8hmut does not per-
mit to measure the effect of PARs on the cleavage and
religation activity and indicates that elimination of eight
hydrophobic residues induces a conformational change
that is enough to inactivate the protein but not to elim-
inate the PAR binding. The cleavage of the wild-type
and 8bmut enzymes was analyzed in the presence or in
the absence of graded concentrations of PARs using a sui-
cide cleavage substrate (Figure 3). In detail, a 5′-end radi-
olabeled oligonucleotide CL14 (5′-GAAAAAAGACTT′
AG-3′) has been annealed to the CP25 (5′-TAAAAATT
TTTCTAAGTCTTTTTTC-3′) complementary strand,
to produce a duplex with an 11-base 5′-single-strand ex-
tension. The enzyme cuts preferentially at the site indi-
cated by the arrow and the religation step is precluded
because the AG-3′ oligonucleotide is too short to be reli-
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Figure 4 Influence of PARs on the kinetics of religation. A. Time course
R11 DNA strand and the enzyme covalent complexes described at the top of
6–9) or 50 pmol PARs (lanes 10–13) and PARs plus CPT (lanes 14–17). Lane 1:
fragment cleaved at the preferred site. B. Plots of the percentage of disappea
symbol) and 8bmut (circle symbols), in the absence (yellow lines) or presence
shown are means ± SD from 3 independent experiments.to the 3′-end and becomes trapped in the covalent com-
plex, permitting to measure the protein cleavage efficiency
by quantification of the band corresponding to the cut
DNA, because of the different migration when compared
to the uncleaved one (Figure 3). The results indicate that,
although the mutant protein has a cutting efficiency 20%
lower than that of the wild-type protein, the cleavage reac-
tion is reduced by PARs in a dose-dependent manner.
Noteworthy, 50 pmol PARs almost abrogate the cleavage
of both the 8bmut and the wild-type proteins.
The DNA religation step has been studied testing the
ability of the wild-type protein and the 8bmut to religate
the R11 (5′-AGAAAAATTTT-3′) oligonucleotide added
to the cleaved suicide substrate previously incubated
with an excess of enzyme. The religation has been ana-
lyzed in the presence of DMSO, PARs, CPT or PARs
plus CPT. Aliquots have been removed at different
times, the reaction stopped by addition of SDS and the
products analyzed by PAGE electrophoresis (Figure 4A).
The percentage of the remaining covalent complex (Cl),
normalized to the value at t = 0, is plotted as a function
of time in Figure 4B. The results show that the 8bmut
has a slower religation rate compared to the wild-type
protein (lanes 2–5), as expected due to the introductionWild-type
8bmut
1     2     4    8     2     4    8  
PAR PAR+CPT






14   15   16   17    11  12   13  
(1–8 min) of the religation experiment between the complementary
the figure, in the absence (lanes 2–5) or presence of 100 μM CPT (lanes
no R11 added; lane 18: no protein added. Cl represents the DNA
rance of the cleavage complex relative to time 0, for the wild-type (square
of CPT (blue lines), PARs (green lines) and PARs plus CPT (red lines). Data
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addition of PARs to the reaction mixture enhances the
religation rate similarly to the wild-type protein (lanes
10–13). CPT inhibits in both enzymes the religation step
(lanes 6–9) that is restored in presence of PARs (lanes 14–
17), as also shown by the quantitative plot of Figure 4B.
These findings are consistent with the antagonistic effects
exerted by PARs on the activity of hTop1 poisons [10].
Overall these data indicate that the mutation of eight
hydrophobic or of eight charged residues present in the
three hTop1 putative PBM does not abolish the PAR-
protein interaction, and that in the case of the 8bmut,
that retains the enzymatic activity, PARs inhibit the
cleavage and enhance the religation identically as in the
wild-type protein. This implies either the presence of
additional PAR binding sites or that the drastic muta-
tions are not able to abolish the PAR-protein interaction,
even though, in the case of the 8hmut, they fully abolish
the enzymatic activity. A study carried out on 22 amino
acids long peptides, containing the supposed hTop1 PAR
binding motif with the same sequences of the ones re-
ported in Figure 1, revealed the absence of any inter-
action with PAR [26], suggesting that these peptides do
not represent the PAR binding motifs. However, a care-
ful bioinformatics analysis of the protein sequence and
structure does not provide any evidence for the presence
of additional known PAR binding sites. Our results show
that the native protein efficiently binds PAR, indicating
the importance to study the interaction in the full pro-
tein. In addition, the protein still efficiently binds PAR
even after the very strong perturbation due to the elim-
ination of the hydrophobic or charged residues able, in
the case of the 8hmut, to fully abolish the enzyme func-
tion, leaving open the question whether the protein
contains additional unknown PAR binding sites.Conclusions
PARP inhibitors, such as veliparib, olaparib and BMN-
673, are currently in phase 1 and 2 clinical trials in com-
bination with irinotecan and topotecan to assess their
safety and efficacy [www.clinicaltrials.gov]. Our data sug-
gest that the presence of mutations at eight basic amino
acids of the three putative PBM does not interfere with
the ability of PARs to exert antagonistic effects on
hTop1 poisons and, indirectly, with the chemosensitizing
effects exerted by PARP inhibitors.Abbreviations
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